找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Key Statistical Concepts in Clinical Trials for Pharma; J. Rick Turner Book 2012 The Author(s) 2012 Clinical Trials.Pharma.Statistical Con

[復(fù)制鏈接]
樓主: HEMI
11#
發(fā)表于 2025-3-23 09:54:54 | 只看該作者
Assessing Efficacy Data,n of clinical concern. Efficacy is assessed in two ways: there must be compelling evidence of both statistically significant efficacy and clinically significant efficacy. The former is addressed via formalized hypothesis testing involving the creation of a research question, a research hypothesis, a
12#
發(fā)表于 2025-3-23 14:01:25 | 只看該作者
13#
發(fā)表于 2025-3-23 20:26:24 | 只看該作者
Meta-Methodology,me research question. It commonly involves not only the statistical combination of summary statistics from various trials (study-level data), but also refers to analyses performed on the combination of subject-level data. Reasons for employing this methodology include: providing a more precise estim
14#
發(fā)表于 2025-3-24 00:30:03 | 只看該作者
,Benefit–Risk Estimation,rapy. It requires consideration of both benefit and risk. For a drug to receive regulatory approval, the regulatory agency must find a drug to have a favorable benefit–risk profile: The benefit to the population as a whole must outweigh any potential risk to certain individuals, who will be protecte
15#
發(fā)表于 2025-3-24 05:50:32 | 只看該作者
J. Rick TurnerDiscusses key statistical concepts.Includes supplementary material:
16#
發(fā)表于 2025-3-24 10:07:30 | 只看該作者
SpringerBriefs in Pharmaceutical Science & Drug Developmenthttp://image.papertrans.cn/k/image/542590.jpg
17#
發(fā)表于 2025-3-24 11:18:55 | 只看該作者
Key Statistical Concepts in Clinical Trials for Pharma978-1-4614-1662-3Series ISSN 1864-8118 Series E-ISSN 1864-8126
18#
發(fā)表于 2025-3-24 18:46:22 | 只看該作者
https://doi.org/10.1007/978-1-4614-1662-3Clinical Trials; Pharma; Statistical Concepts; Statistics
19#
發(fā)表于 2025-3-24 22:26:14 | 只看該作者
20#
發(fā)表于 2025-3-25 01:28:43 | 只看該作者
Book 2012prove a new drug for marketing) and the individual patient level (by physicians and their patients when deciding whether or not the patient should be prescribed a drug that is on the market). These concepts include drug safety and efficacy, statistical significance, clinical significance, and benefit-risk balance.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-9 11:20
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
抚顺县| 鄱阳县| 阿克陶县| 五峰| 庆云县| 安泽县| 南昌县| 沙洋县| 西贡区| 乌兰县| 祁门县| 潜山县| 昂仁县| 禹城市| 南雄市| 无极县| 桃江县| 洛扎县| 辉县市| 神农架林区| 抚州市| 宣恩县| 霍山县| 富蕴县| 论坛| 通山县| 青海省| 巴马| 景谷| 荥经县| 龙海市| 鸡西市| 定结县| 图木舒克市| 都昌县| 龙井市| 龙江县| 丹阳市| 沅陵县| 行唐县| 阜阳市|